V Rosato1, C Bosetti2, R Talamini3, F Levi4, M Montella5, A Giacosa6, E Negri1, C La Vecchia7. 1. Department of Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri, Milan. 2. Department of Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri, Milan. Electronic address: cristina.bosetti@marionegri.it. 3. Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy. 4. Cancer Epidemiology Unit and Cancer Registry of Vaud, Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland. 5. Department of Epidemiology, Istituto Nazionale Tumori "Fondazione Pascale", Naples. 6. Department of Gastroenterology and Nutrient Unit, Policlinico di Monza, Monza. 7. Department of Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Department of Occupational Medicine, Università degli Studi di Milano, Milan, Italy; International Prevention Research Institute, Lyon, France.
Abstract
BACKGROUND: Only a few small studies investigated the association between postmenopausal breast cancer and metabolic syndrome (MetS) as a single entity. MATERIALS AND METHODS: We analyzed the data of two Italian and Swiss case-control studies conducted between 1983 and 2007, including 3869 postmenopausal women with incident breast cancer and 4082 postmenopausal controls admitted to the same hospitals as cases for acute conditions. MetS was defined as the presence of at least three components among diabetes, drug-treated hypertension, drug-treated hyperlipidemia, and obesity. RESULTS: The odds ratios (ORs) of postmenopausal breast cancer were 1.33 [95% confidence interval (CI) 1.09-1.62] for diabetes, 1.19 (95% CI 1.07-1.33) for hypertension, 1.08 (95% CI 0.95-1.22) for hyperlipidemia, 1.26 (95% CI 1.11-1.44) for body mass index ≥30 kg/m(2), and 1.22 (95% CI 1.09-1.36) for waist circumference ≥88 cm. The risk of postmenopausal breast cancer was significantly increased for women with MetS (OR = 1.75, 95% CI 1.37-2.22, for three or more MetS components, P for trend for increasing number of components < 0.0001) and the risk was higher at older age (OR = 3.04, 95% CI 1.75-5.29, at age ≥70 years for three or more MetS components). CONCLUSIONS: This study supports a direct association between MetS and postmenopausal breast cancer risk.
BACKGROUND: Only a few small studies investigated the association between postmenopausal breast cancer and metabolic syndrome (MetS) as a single entity. MATERIALS AND METHODS: We analyzed the data of two Italian and Swiss case-control studies conducted between 1983 and 2007, including 3869 postmenopausal women with incident breast cancer and 4082 postmenopausal controls admitted to the same hospitals as cases for acute conditions. MetS was defined as the presence of at least three components among diabetes, drug-treated hypertension, drug-treated hyperlipidemia, and obesity. RESULTS: The odds ratios (ORs) of postmenopausal breast cancer were 1.33 [95% confidence interval (CI) 1.09-1.62] for diabetes, 1.19 (95% CI 1.07-1.33) for hypertension, 1.08 (95% CI 0.95-1.22) for hyperlipidemia, 1.26 (95% CI 1.11-1.44) for body mass index ≥30 kg/m(2), and 1.22 (95% CI 1.09-1.36) for waist circumference ≥88 cm. The risk of postmenopausal breast cancer was significantly increased for women with MetS (OR = 1.75, 95% CI 1.37-2.22, for three or more MetS components, P for trend for increasing number of components < 0.0001) and the risk was higher at older age (OR = 3.04, 95% CI 1.75-5.29, at age ≥70 years for three or more MetS components). CONCLUSIONS: This study supports a direct association between MetS and postmenopausal breast cancer risk.
Authors: Katherine W Reeves; Vicki McLaughlin; Lisa Fredman; Kristine Ensrud; Jane A Cauley Journal: Cancer Causes Control Date: 2012-06-02 Impact factor: 2.506
Authors: Neil M Iyengar; Patrick G Morris; Xi Kathy Zhou; Ayca Gucalp; Dilip Giri; Michael D Harbus; Domenick J Falcone; Margaret D Krasne; Linda T Vahdat; Kotha Subbaramaiah; Monica Morrow; Clifford A Hudis; Andrew J Dannenberg Journal: Cancer Prev Res (Phila) Date: 2015-02-26
Authors: Yong-Moon Mark Park; Alexandra J White; Hazel B Nichols; Katie M O'Brien; Clarice R Weinberg; Dale P Sandler Journal: Int J Cancer Date: 2017-03-28 Impact factor: 7.396
Authors: K Sevcikova; Z Zhuang; G Garcia-Manero; R H Alvarez; H M Kantarjian; M Mego; C Albarracin; G Tang; S S Strom; L J Medeiros; G N Hortobagyi; J M Reuben; J D Khoury Journal: Leukemia Date: 2015-05-15 Impact factor: 11.528
Authors: Jaclyn L F Bosco; Julie R Palmer; Deborah A Boggs; Elizabeth E Hatch; Lynn Rosenberg Journal: Breast Cancer Res Treat Date: 2012-06-19 Impact factor: 4.872